ES2153816T3 - Adn que codifica un factor de crecimiento especifico contra celulas epiteliales. - Google Patents

Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.

Info

Publication number
ES2153816T3
ES2153816T3 ES90903253T ES90903253T ES2153816T3 ES 2153816 T3 ES2153816 T3 ES 2153816T3 ES 90903253 T ES90903253 T ES 90903253T ES 90903253 T ES90903253 T ES 90903253T ES 2153816 T3 ES2153816 T3 ES 2153816T3
Authority
ES
Spain
Prior art keywords
growth factor
cells
protein
epithelial cells
dna coding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90903253T
Other languages
English (en)
Inventor
Jeffrey S Rubin
Paul W Finch
Stuart A Aaronson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23175833&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2153816(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2153816T3 publication Critical patent/ES2153816T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/501—Fibroblast growth factor [FGF] acidic FGF [aFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

SE DESCRIBEN DESCUBRIMIENTOS QUE MUESTRAN QUE ASPECTOS PARTICULARES O LA TECNOLOGIA RECOMBINANTE DEL DNA SE PUEDEN USAR CON EXITO PARA PRODUCIR LA PROTEINA DEL FACTOR DE CRECIMIENTO HUMANO QUERATINOCITA (KGF) DESCONOCIDA HASTA AHORA, EXENTA DE OTROS POLIPEPTIDOS. ESTAS PROTEINAS PUEDEN SER PRODUCIDAS DE VARIAS FORMAS FUNCIONALES A PARTIR DE SECRECION ESPONTANEA O A PARTIR DE SEGMENTOS DE DNA INTRODUCIDOS EN LAS CELULAS. ESTAS FORMAS PERMITEN DIFERENTES ESTUDIOS BIOQUIMICOS Y FUNCIONALES DE ESTA NUEVA PROTEINA, ASI COMO LA PRODUCCION DE ANTICUERPOS. SE DESCRIBEN MEDIOS PARA DETERMINAR EL NIVEL DE EXPRESION DE GENES PARA LA PROTEINA KGF, POR EJEMPLO, MEDIANTE MEDICION DE LOS NIVLES MRNA EN CELULAS O POR MEDICION DE ANTIGENOS SECRETADOS FUERA DE LAS CELULAS O FLUIDOS CORPORALES.
ES90903253T 1989-01-31 1990-01-30 Adn que codifica un factor de crecimiento especifico contra celulas epiteliales. Expired - Lifetime ES2153816T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30428189A 1989-01-31 1989-01-31

Publications (1)

Publication Number Publication Date
ES2153816T3 true ES2153816T3 (es) 2001-03-16

Family

ID=23175833

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90903253T Expired - Lifetime ES2153816T3 (es) 1989-01-31 1990-01-30 Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.

Country Status (22)

Country Link
US (8) US6420531B1 (es)
EP (2) EP1016716A3 (es)
JP (6) JP3298874B2 (es)
KR (1) KR950012805B1 (es)
AT (1) ATE197800T1 (es)
AU (2) AU647732B2 (es)
CA (2) CA2038398C (es)
DE (2) DE69033668T2 (es)
DK (1) DK0555205T3 (es)
ES (1) ES2153816T3 (es)
FI (1) FI114711B (es)
GE (1) GEP20022681B (es)
HU (1) HU218090B (es)
IE (1) IE20020188A1 (es)
LT (1) LT3472B (es)
LU (1) LU91237I2 (es)
LV (1) LV10284B (es)
NL (1) NL300230I2 (es)
NO (2) NO308312B1 (es)
RU (1) RU2250213C2 (es)
SG (1) SG46699A1 (es)
WO (1) WO1990008771A1 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1016716A3 (en) 1989-01-31 2000-07-12 RUBIN, Jeffrey S Dna encoding a growth factor specific for epithelial cells
GB9203533D0 (en) * 1992-02-19 1992-04-08 Erba Carlo Spa Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
UA46706C2 (uk) * 1993-03-26 2002-06-17 Амген Інк. Спосіб лікування та запобігання хворобливому стану пацієнта, фармацевтична композиція
US5965530A (en) * 1993-03-26 1999-10-12 Amgen Inc. Therapeutic uses of keratinocyte growth factor
US7084119B2 (en) 1993-06-29 2006-08-01 Chiron Corporation Truncated keratinocyte growth factor (KGF) having increased biological activity
CA2166278A1 (en) * 1993-06-29 1995-01-12 Denis J. Gospodarowicz A truncated keratinocyte growth factor (kgf) having increased biological activity
US6268212B1 (en) 1993-10-18 2001-07-31 Amgen Inc. Tissue specific transgene expression
US6008328A (en) * 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
WO1996011949A2 (en) * 1994-10-13 1996-04-25 Amgen Inc. Analogs of keratinocyte growth factor
EP0785949B1 (en) * 1994-10-13 2003-05-02 Amgen Inc. Method for purifying keratinocyte growth factors
ES2196088T3 (es) * 1994-10-13 2003-12-16 Amgen Inc Analogos del factor de crecimiento de los queratinocitos.
US6818439B1 (en) 1994-12-30 2004-11-16 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US7232667B2 (en) 1995-02-14 2007-06-19 Human Genome Sciences, Inc. Keratinocyte growth factor-2 polynucleotides
US6077692A (en) 1995-02-14 2000-06-20 Human Genome Sciences, Inc. Keratinocyte growth factor-2
US6693077B1 (en) 1995-02-14 2004-02-17 Human Genome Sciences, Inc. Keratinocyte growth factor-2
ES2224178T3 (es) 1995-10-11 2005-03-01 Chiron Corporation Cobinacion de pdgf, kgf,igf e igfbp para la cicatrizacion de heridas.
US6692961B1 (en) 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US20030144202A1 (en) * 1996-10-15 2003-07-31 Amgen Inc. Uses of keratinocyte growth factor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
DE19716098A1 (de) * 1997-04-17 1998-10-22 Univ Ludwigs Albert Fibroblasten mit einem Fremdgen enthaltende Zusammensetzung zur Behandlung von Wunden
US6228839B1 (en) 1997-12-19 2001-05-08 Emory University Use of keratinocyte growth factor to improve oxidative status
US6238888B1 (en) 1997-12-22 2001-05-29 Human Genone Sciences, Inc. Keratinocyte growth factor-2 formulations
US6869927B1 (en) 1997-12-22 2005-03-22 Human Genome Sciences, Inc. Keratinocyte growth factor-2 formulations
EP1054900A4 (en) * 1998-02-13 2004-12-22 Human Genome Sciences Inc THERAPEUTIC USE OF THE KERATINOCTENT GROWTH FACTOR-2
US6335317B1 (en) 1998-04-10 2002-01-01 Emory University Use of gut-trophic growth factors to improve oxidative status
US7022683B1 (en) 1998-05-13 2006-04-04 Carrington Laboratories, Inc. Pharmacological compositions comprising pectins having high molecular weights and low degrees of methoxylation
US5929051A (en) * 1998-05-13 1999-07-27 Carrington Laboratories, Inc. Aloe pectins
US6313103B1 (en) 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
US6783546B2 (en) 1999-09-13 2004-08-31 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US6371984B1 (en) 1999-09-13 2002-04-16 Keraplast Technologies, Ltd. Implantable prosthetic or tissue expanding device
US6395414B1 (en) 2000-02-11 2002-05-28 General Motors Corporation Staged venting of fuel cell system during rapid shutdown
US6376112B1 (en) 2000-02-11 2002-04-23 General Motors Corporation Controlled shutdown of a fuel cell
US6413662B1 (en) 2000-02-22 2002-07-02 General Motors Corporation Fuel cell system shutdown with anode pressure control
JP2001302691A (ja) * 2000-04-17 2001-10-31 Nichirei Corp ヒトｋｇｆに対する抗体
US20030186904A1 (en) * 2001-01-08 2003-10-02 Human Genome Sciences, Inc. Keratinocyte growth factor-2
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
US7494669B2 (en) 2001-02-28 2009-02-24 Carrington Laboratories, Inc. Delivery of physiological agents with in-situ gels comprising anionic polysaccharides
PL374269A1 (en) 2001-08-21 2005-10-03 Chiron Corporation Kgf polypeptide compositions
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
GB0206309D0 (en) * 2002-03-16 2002-05-01 Axordia Ltd Isolated cells
AU2003265612A1 (en) * 2002-08-20 2004-03-11 Curagen Corporation Methods for diagnosing and treatment of conditions that alter phosphate transport in mammals
MX2007006822A (es) 2004-12-15 2007-07-24 Amgen Inc Formulaciones terapeuticas para el factor de crecimiento de queratinocitos.
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
CN101679495B (zh) * 2007-01-05 2013-07-17 赫里克斯生物医疗公司 用于细胞学和免疫学调节的短的生物活性肽
CN102471769A (zh) 2009-07-17 2012-05-23 亚伦·T.·塔波尔 用于具有美容功能的细胞的遗传修饰以提高美容外观的方法和组合物
US9682093B2 (en) 2012-03-30 2017-06-20 Charles R. Drew University Of Medicine And Science Compositions and methods for treating or preventing metabolic syndrome disorders
KR102277147B1 (ko) * 2017-12-13 2021-07-13 건국대학교 산학협력단 섬유아 성장인자 유래 펩타이드의 골 또는 연골 분화 촉진 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096825A (en) * 1983-01-12 1992-03-17 Chiron Corporation Gene for human epidermal growth factor and synthesis and expression thereof
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
US4473679A (en) 1983-12-12 1984-09-25 Borg-Warner Chemicals, Inc. Thermoplastic acrylic elastomers
US4743679A (en) * 1986-02-24 1988-05-10 Creative Biomolecules, Inc. Process for producing human epidermal growth factor and analogs thereof
US4868113A (en) 1986-03-03 1989-09-19 Rorer Biotechnology, Inc. Recombinant DNA vector encoding human endothelial cell growth factor
US4983679A (en) 1986-05-29 1991-01-08 E. I. Dupont De Nemours And Company β-(keto or sulfonyl)esters from reaction of silylketene acetal and acyl or sulfonyl compound
WO1989008666A1 (en) 1988-03-17 1989-09-21 Novo-Nordisk A/S Heparin-binding proteins, dna cuding for them, processes for producing them as well as therapeutic preparations containing them
EP1016716A3 (en) 1989-01-31 2000-07-12 RUBIN, Jeffrey S Dna encoding a growth factor specific for epithelial cells
CA2166278A1 (en) * 1993-06-29 1995-01-12 Denis J. Gospodarowicz A truncated keratinocyte growth factor (kgf) having increased biological activity
WO1996011949A2 (en) 1994-10-13 1996-04-25 Amgen Inc. Analogs of keratinocyte growth factor

Also Published As

Publication number Publication date
US5731170A (en) 1998-03-24
DE69033668D1 (de) 2001-01-04
NO308310B1 (no) 2000-08-28
DE122006000021I1 (de) 2006-07-13
US5741642A (en) 1998-04-21
EP0555205B1 (en) 2000-11-29
LU91237I2 (fr) 2007-02-22
DE69033668T2 (de) 2001-04-12
IE20020188A1 (en) 2002-06-26
NO972617L (no) 1997-06-06
CA2038398A1 (en) 1992-09-16
AU647732B2 (en) 1994-03-31
WO1990008771A1 (en) 1990-08-09
HUT58759A (en) 1992-03-30
EP0555205A4 (en) 1992-06-02
LTIP667A (en) 1995-01-31
NO972617D0 (no) 1997-06-06
JP2716416B2 (ja) 1998-02-18
US6709842B1 (en) 2004-03-23
AU684278B2 (en) 1997-12-11
US5654405A (en) 1997-08-05
JP3298874B2 (ja) 2002-07-08
JP2006149407A (ja) 2006-06-15
NO972259L (no) 1997-05-16
JP2001157594A (ja) 2001-06-12
CA2038398C (en) 2002-01-22
US6833132B1 (en) 2004-12-21
NL300230I2 (nl) 2006-09-01
KR950012805B1 (en) 1995-10-21
JPH04504415A (ja) 1992-08-06
US6420531B1 (en) 2002-07-16
GEP20022681B (en) 2002-04-25
LV10284B (en) 1995-04-20
NO972259D0 (no) 1997-05-16
JP3088983B2 (ja) 2000-09-18
KR910700257A (ko) 1991-03-14
AU5049690A (en) 1990-08-24
RU2250213C2 (ru) 2005-04-20
EP1016716A3 (en) 2000-07-12
DK0555205T3 (da) 2001-03-05
FI114711B (fi) 2004-12-15
FI913637A0 (fi) 1991-07-30
CA2349875C (en) 2010-02-09
AU6598694A (en) 1994-09-08
HU218090B (hu) 2000-05-28
NL300230I1 (nl) 2006-07-03
EP0555205A1 (en) 1993-08-18
LV10284A (lv) 1994-10-20
CA2349875A1 (en) 1992-09-16
JP3802329B2 (ja) 2006-07-26
US5665870A (en) 1997-09-09
US5707805A (en) 1998-01-13
EP1016716A2 (en) 2000-07-05
JPH08277227A (ja) 1996-10-22
LT3472B (en) 1995-10-25
JP2000102396A (ja) 2000-04-11
ATE197800T1 (de) 2000-12-15
SG46699A1 (en) 1998-02-20
NO308312B1 (no) 2000-08-28
JPH10243800A (ja) 1998-09-14
JP3802292B2 (ja) 2006-07-26

Similar Documents

Publication Publication Date Title
ES2153816T3 (es) Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
ATE110108T1 (de) Genetische modifizierung von endothelialen zellen.
ES2190787T3 (es) Represor regulado por el ciclo celular y elemento de adn.
AR247761A1 (es) Metodo para producir un polipeptido en una celula hospedante de kluyveromyces, dicha celula hospedante transformada y secuencia a adn empleada
NO20032674D0 (no) Isoindolin-1-on-glukokinase-aktivatorer
ATE245437T1 (de) Wachstumsfaktor-b, spezifisch für vaskuläre endothelzellen
ES2094159T3 (es) Produccion de factor de crecimiento de celulas endoteliales vasculares.
UA81398C2 (en) Keratinocytes which may be used as biologically active substances for the treatment of wounds
DE68923556D1 (de) Säureempfindliche subeinheit eines insulinähnlichen wachstumfaktors-bindeprotein-komplexes.
DE69132530D1 (de) Heparin bindendes mitogen mit homologie zum epidermis wachstumsfaktor (egf)
DE69329195D1 (de) Rekombinante dna moleküle die aminopeptidase enzyme kodieren und ihre anwendung für die herstellung von impfstoffen gegen helminth infektionen
ATE15445T1 (de) System zur produktion von cystein.
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
TR200201119T2 (tr) İnsan alfa1G-C-türü kalsiyum kanalı kodlayan DNA.
ES2068325T3 (es) Metodo y juego o kit para determinar la actividad funcional de la proteina s en el plasma humano.
ES2121754T3 (es) Fragmento de adnc que codifica el gen del receptor del interferon alfa y procedimiento para la preparacion de una proteina correspondiente.
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
UA84540C2 (en) Novel cytokine zcytor17 ligand

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 555205

Country of ref document: ES